A Novel Surgical Strategy to Reduce Major Complications in Patients With Necrotizing Pancreatitis
NCT06241586 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 271
Last updated 2024-02-05
Summary
The goal of this observational study is to compare patient outcomes between the groups of patients admitted before and after the full implementation of the novel surgical strategy in patients with necrotizing pancreatitis. The main question it aims to answer are:
• the efficacy and safety of the novel surgical strategy To assess the efficacy and safety of the novel surgical strategy, all included patients were divided into two groups according to the timing of receiving treatment: 1) the early period group: patients admitted before January 2021 received the hybrid strategy of traditional and novel surgical strategies; and 2) the late period group: patients admitted during and after January 2021 received the complete novel surgical strategy.
Conditions
Interventions
- PROCEDURE
-
The novel PMMI surgical strategy
Immediate drainagewas advocated within 24 hours once necrosis was diagnosed. During the treatment course, a hybrid approach was available by flexibly switching interventions. Open surgery was only applied when patients required emergency surgery. The minimally invasive surgery was selected based on the size, location, and maturity of the necrotic area and stepwise response to intervention. Repeated peritoneal purification was performed until the infected or devitalized tissue was controlled. Patients were subsequently discharged with a drainage catheter and readmitted at 7- to 10-day intervals to receive repeated planned surgery without postoperative irrigation. Patients received a whole-course assessment for individual patients at 7-day predetermined intervals.
- PROCEDURE
-
The conventional step-up strategy
Interventions were postponed until 4 weeks after the onset of pancreatitis in line with international guidelines unless the patient showed evidence of progressive clinical deterioration despite the use of maximal supportive care. Patients underwent CT-guided percutaneous catheter drainage as the first step. Treatment response was evaluated after 3 days. If drainage was clinically unsuccessful, a VARD procedure was performed. Similarly, open surgery, which was described by Beger et al., was performed if the VARD procedure failed. Postoperative continuous lavage is performed as a routine procedure.
Sponsors & Collaborators
-
Tianjin Nankai Hospital
lead OTHER
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2019-01-01
- Primary Completion
- 2021-12-31
- Completion
- 2022-10-01
Countries
- China
Study Locations
More Related Trials
-
Nimotuzumab Combined With mFOLFIRINOX/GX as Postoperative Adjuvant Therapy in Pancreatic Cancer
NCT06389760 ·Status: RECRUITING ·Phase: PHASE2
-
Risk Factors of Postoperative Complications and Survival Rate in Pancreatic Ductal Adenocarcinoma Patients
NCT06378853 ·Status: COMPLETED
-
Related Studies of Imaging Features and Prognosis Between Pancreatic Neuroendocrine Tumors and Pancreatic Cancer
NCT04977596 ·Status: COMPLETED
-
Pancreas-sparing Duodenectomy Versus Pancreatoduodenectomy for Early-stage Periampullary Carcinoma
NCT01291927 ·Status: UNKNOWN ·Phase: NA
-
A New Strategy for Preoperative Drainage of Resectable Pancreatic Head Cancer Combined Severe Obstructive Jaundice
NCT06541340 ·Status: RECRUITING ·Phase: NA
-
A New Prognostic Score Model for Pancreatic Ductal Adenocarcinoma
NCT05547074 ·Status: COMPLETED
-
Thymosin Alpha 1 in the Prevention of Pancreatic Infection Following Acute Necrotizing Pancreatitis
NCT02473406 ·Status: COMPLETED ·Phase: PHASE4
-
Intermittent Fasting for Pancreatitis
NCT04760847 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
The Significance and Indications of Surgery for Synchronous Liver Metastatic Pancreatic Cancer
NCT06873178 ·Status: ACTIVE_NOT_RECRUITING
-
Ki67 Proliferation Index of Pancreatic Neuroendocrine Neoplasia
NCT04753229 ·Status: COMPLETED
-
The Comparision of Minimally-invasive and Open Pancreaticoduodenectomy for Pancreatic Cancer
NCT03747588 ·Status: RECRUITING ·Phase: NA
-
Studying Fibroblast Activity in Patients With Localized Pancreatic Cancer Undergoing Surgery
NCT00900016 ·Status: COMPLETED
-
Multimodal Therapy Impact on Pancreatic Cancer Survival
NCT06938906 ·Status: ACTIVE_NOT_RECRUITING
-
Early Recurrence After Surgery for Pancreatic Cancer
NCT07241676 ·Status: ENROLLING_BY_INVITATION
-
Selective Extended Dissection in Different Types of Pancreatic Head Cancer: A Retrospective Cohort Study.
NCT05723978 ·Status: COMPLETED
-
Conventional Partial Pancreatoduodenectomy Versus an Extended Pancreatoduodenectomy for Pancreatic Head Cancers
NCT06703905 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Long-term Prognosis for Non-functional Neuroendocrine Tumors of the Pancreatic Body and Tail ≤ 3cm
NCT05907824 ·Status: UNKNOWN
-
Combined Resection vs. Separated Resection After Mobilization of Splenic Vein During Distal Pancreatectomy
NCT02871804 ·Status: UNKNOWN ·Phase: PHASE3
-
Nimotuzumab Combined With GX as Postoperative Adjuvant Therapy in Pancreatic Cancer
NCT06409429 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2/PHASE3
-
Gemcitabine and Celecoxib Combination Therapy in Treating Patients With R0 Resection Pancreatic Cancer
NCT03498326 ·Status: RECRUITING ·Phase: PHASE2
-
Clinician Decision Making Regarding Surveillance for Low-risk Intraductal Papillary Mucinous Neoplasms of The Pancreas
NCT06311032 ·Status: COMPLETED
-
Phase I Study of Neoadjuvant Chemotherapy for Patients With Borderline Resectable Pancreatic Cancer.
NCT02506803 ·Status: UNKNOWN ·Phase: PHASE1
-
Prognostic and Predictive Biomarkers of Therapeutic Response in Pancreatic Tumors
NCT01692873 ·Status: COMPLETED ·Phase: NA
-
Neoadjuvant Chemotherapy for Pancreatic Cancer Followed by GS and GnP
NCT05268692 ·Status: RECRUITING ·Phase: PHASE2/PHASE3
-
Vapreotide in Treating Patients Undergoing Elective Pancreatic Resection
NCT00014651 ·Status: TERMINATED ·Phase: PHASE3